Table 1:

Results of Economic Literature Review for Fecal Microbial Therapy—Summary

Name, Year, Location	Study Design, Time Horizon, and Perspective	Population and Indication	Interventions and Comparators	Results
				Health Outcomes QALYs, Cure Rates	Costs	Cost-Effectiveness
Varier et al, 201525 United States	Design Decision-analytic model Time horizon 90 days Perspective Third-party payer	Population RCDI patients Indication FMT for first-line treatment of RCDI patients	Interventions FMT colonoscopy Comparator Vancomycin	FMT 0.242 83%–100% Vancomycin 0.235 59%–75%	FMT $1,669 vs. vancomycin $3,788 Discount No discounting necessary because simulated patients in model were followed for 90 days	Dominant
Konijeti et al, 201426 United States	Design Decision-analytic model comparing 4 treatment strategies for first-line treatment of RCDI Time horizon 1 year Perspective Societal	Population RCDI patients Indication FMT for first-line treatment of RCDI in hypothetical cohort	Interventions FMT colonoscopy Comparators Metronidazole, vancomycin, fidaxomicin	FMT 0.8719, 94.5% Vancomycin 0.8580, 91.6% Metronidazole 0.8292, 71% Fidaxomicin 0.8653, 93.7%	Cost FMT $3,149 Vancomycin $2,912 Metronidazole $3,941 Fidaxomicin $4,261 Discount No discounting necessary because simulated patients in model were followed for 1 year	FMT compared with vancomycin: ICER $17,016 per QALY FMT vs. metronidazole Dominant FMT vs. fidaxomicin Dominant

Abbreviations: FMT, fecal microbiota transplant; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; RCDI, recurrent Clostridium difficile infection.